Remove 2004 Remove Pharma Remove Safety
article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. You can compare timelines.

Pharma 64
article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. The pandemic raised the sector’s profile and has helped establish pharma as a desirable career path for several reasons, including job security, innovation, and societal value.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. This is reflected in the legal basis for biosimilars under Article 6 of Regulation 726/2004 and Article 10(4) of Directive 2001/83 (as amended by Directive 2004/27).

article thumbnail

The Dark Side of KOL Relationship

Contrarian Sales Techniques

However, it was later discovered that the drug increased the risk of heart attacks and strokes, and it was eventually pulled from the market in 2004. Another example is the case of Purdue Pharma and the opioid crisis. No sale is worth risking your health or safety.

Ethics 52
article thumbnail

The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next

PM360

This was back in 2004/2005 when we were just hearing about biosimilars for the first time and they were the great unknowns. But now the big pharma companies have also jumped into the game. Ultimately, we want to establish ourselves as that one specialty pharma company in the U.S. So their battle test is high.

article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

Oncoral (Ascelia Pharma) is a novel patented tablet formulation of irinotecan, currently in Phase II clinical development, for daily dosing at home. Secondary endpoints will include response rate, overall survival, pharmacokinetics, safety and tolerability. J Clin Oncol, 2004; 22(14): 2849-2855. About the author.

Patients 104
article thumbnail

Delivering Improved Disease Awareness Through More Strategic Partnerships

PM360

Can more than 20 pharma companies unite around messaging for biomarker testing even though everyone seems to call it something different? Historically, pharma companies only do marketing for biomarker testing related to the type of drug they were launching,” says Nikki Martin, Senior Director, Precision Medicine Initiatives, LUNGevity. “As

Education 105